Clinical Trial Update: Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells

View source ↗

Summary

The Celution device cardiac registry trial for processing adipose-derived regenerative cells in heart failure and coronary artery disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Heart Failure

Snippet

Sponsor: Cytori Therapeutics | Conditions: Heart Failure, Coronary Artery Disease | Status: WITHDRAWN